Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men

详细信息    查看全文

• 作者：Ashley E. Ross^a ; ^{aross2@jhni.edu" class="auth_mail" title="E-mail the corresponding author} ; Kasra Yousefi^b ; Elai Davicioni^b ; Mercedeh Ghadessi^b ; Michael H. Johnson^a ; Debasish Sundi^a ; Jeffery J. Tosoian^a ; Misop Han^a ; Elizabeth B. Humphreys^a ; Alan W. Partin^a ; Patrick C. Walsh^a ; Bruce J. Trock^a ; Edward M. Schaeffer^a
• 关键词：Prostate cancer ; Adverse pathologic features ; Biochemical recurrence ; Metastasis ; Adjuvant therapy ; Salvage therapy ; Nomograms
• 刊名：European Urology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：69
• 期：3
• 页码：496-504
• 全文大小：1801 K

文摘

Current guidelines suggest adjuvant radiation therapy for men with adverse pathologic features (APFs) at radical prostatectomy (RP). We examine at-risk men treated only with RP until the time of metastasis.

Objective

To evaluate whether clinicopathologic risk models can help guide postoperative therapeutic decision making.

Design, setting, and participants

Men with National Comprehensive Cancer Network intermediate- or high-risk localized prostate cancer undergoing RP in the prostate-specific antigen (PSA) era were identified (n = 3089). Only men with initial undetectable PSA after surgery and who received no therapy prior to metastasis were included. APFs were defined as pT3 disease or positive surgical margins.

Outcome measurements and statistical analysis

Area under the receiver operating characteristic curve (AUC) for time to event data was used to measure the discrimination performance of the risk factors. Cumulative incidence curves were constructed using Fine and Gray competing risks analysis to estimate the risk of biochemical recurrence (BCR) or metastasis, taking censoring and death due to other causes into consideration.

Results and limitations

Overall, 43% of the cohort (n = 1327) had APFs at RP. Median follow-up for censored patients was 5 yr. Cumulative incidence of metastasis was 6% at 10 yr after RP for all patients. Cumulative incidence of metastasis among men with APFs was 7.5% at 10 yr after RP. Among men with BCR, the incidence of metastasis was 38% 5 yr after BCR. At 10 yr after RP, time-dependent AUC for predicting metastasis by Cancer of the Prostate Risk Assessment Postsurgical or Eggener risk models was 0.81 (95% confidence interval [CI], 0.72–0.97) and 0.78 (95% CI, 0.67–0.97) in the APF population, respectively. At 5 yr after BCR, these values were lower (0.58 [95% CI, 0.50–0.66] and 0.70 [95% CI, 0.63–0.76]) among those who developed BCR. Use of risk model cut points could substantially reduce overtreatment while minimally increasing undertreatment (ie, use of an Eggener cut point of 2.5% for treatment of men with APFs would spare 46% from treatment while only allowing for metastatic events in 1% at 10 yr after RP).

Conclusions

Use of risk models reduces overtreatment and should be a routine part of patient counseling when considering adjuvant therapy. Risk model performance is significantly reduced among men with BCR.

Patient summary

Use of current risk models can help guide decision making regarding therapy after surgery and reduce overtreatment.